Vericel Corporation (VCEL) is a Biotechnology company in the Healthcare sector, currently trading at $35.37. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of VCEL = $171.43 (+384.7% from the current price, the stock appears undervalued). Analyst consensus target is VCEL = $46 (+28.6% upside).
Valuation: VCEL trades at a trailing Price-to-Earnings (P/E) of 102.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.23.
Financials: revenue is $276M, +18.9%/yr average growth. Net income is $17M, growing at +188.7%/yr. Net profit margin is 6% (thin). Gross margin is 74.4% (+7.6 pp trend).
Balance sheet: total debt is $98M against $355M equity (Debt-to-Equity (D/E) ratio 0.28, conservative). Current ratio is 5.03 (strong liquidity). Debt-to-assets is 20.1%. Total assets: $488M.
Analyst outlook: 9 / 14 analysts rate VCEL as buy (64%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 52/100 (Partial), Growth 90/100 (Pass), Past 50/100 (Partial), Health 83/100 (Pass), Moat 70/100 (Pass), Future 67/100 (Pass), Income 45/100 (Partial).
